- Home
- IOVA vs HASI Comparison
IOVA vs HASI Comparison
Compare IOVA & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- HASI
- Stock Information
- Founded
- IOVA 2007
- HASI 1981
- Country
- IOVA United States
- HASI United States
- Employees
- IOVA N/A
- HASI N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- HASI Real Estate Investment Trusts
- Sector
- IOVA Health Care
- HASI Real Estate
- Exchange
- IOVA Nasdaq
- HASI Nasdaq
- Market Cap
- IOVA 771.4M
- HASI 3.4B
- IPO Year
- IOVA N/A
- HASI 2013
- Fundamental
- Price
- IOVA $1.74
- HASI $27.26
- Analyst Decision
- IOVA Buy
- HASI Strong Buy
- Analyst Count
- IOVA 10
- HASI 9
- Target Price
- IOVA $12.22
- HASI $38.33
- AVG Volume (30 Days)
- IOVA 11.7M
- HASI 1.8M
- Earning Date
- IOVA 08-07-2025
- HASI 07-31-2025
- Dividend Yield
- IOVA N/A
- HASI 6.16%
- EPS Growth
- IOVA N/A
- HASI N/A
- EPS
- IOVA N/A
- HASI 1.08
- Revenue
- IOVA $212,679,000.00
- HASI $126,702,000.00
- Revenue This Year
- IOVA $86.62
- HASI $189.49
- Revenue Next Year
- IOVA $69.95
- HASI $14.03
- P/E Ratio
- IOVA N/A
- HASI $25.23
- Revenue Growth
- IOVA 11070.12
- HASI N/A
- 52 Week Low
- IOVA $1.64
- HASI $21.98
- 52 Week High
- IOVA $12.51
- HASI $36.56
- Technical
- Relative Strength Index (RSI)
- IOVA 38.67
- HASI 55.82
- Support Level
- IOVA $1.67
- HASI $26.63
- Resistance Level
- IOVA $1.82
- HASI $28.42
- Average True Range (ATR)
- IOVA 0.12
- HASI 0.87
- MACD
- IOVA -0.00
- HASI 0.10
- Stochastic Oscillator
- IOVA 13.85
- HASI 63.64
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.